Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal ACWY-CRM conjugate vaccine · 1 trial · 1 indication
Immunogenicity was measured as the percentage of subjects with hSBA seroresponse, directed against each of meningococcal serogroups A, C, W and Y, evaluated by serum bactericidal assay using human complement (hSBA), one month after vaccination (day 29)with MenACWY-CRM or MenACWY-PS vaccine. Seroresponse was defined as: 1. for subjects with a prevaccination hSBA titer \<1:4, a postvaccination hSBA titer ≥1:8; 2. for subjects with a prevaccination hSBA titer ≥1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Safety was assessed in terms of the number of subjects who reported at least one severe systemic reaction after vaccination with MenACWY-CRM or MenACWY-PS from day 1 to day 7 after vaccination.
| Arm | Type | Description |
|---|---|---|
| MenACWY-CRM | EXPERIMENTAL | Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) |
| MenACWY-PS | ACTIVE_COMPARATOR | Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS) |
| Name | Type | Description |
|---|---|---|
| Meningococcal ACWY-CRM conjugate vaccine | BIOLOGICAL | MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar. |
| Meningococcal ACWY-PS polysaccharide vaccine | BIOLOGICAL | MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar. |
Inclusion Criteria: * Healthy children 2 to 10 years of age inclusive whose parents or legal guardians gave written informed consent at the time of enrollment; * Available for all visits and telephone calls (parents or legal guardians) scheduled for the study; * Good health as determined by the cli...
Meningococcal ACWY-CRM conjugate vaccine is used for the prevention of meningococcal disease, a serious bacterial infection caused by Neisseria meningitidis. It is designed to protect against serogroups A, C, W, and Y. The vaccine is currently being investigated in a Phase 3 clinical trial for use in children aged 2 to 10 years.
Meningococcal ACWY-CRM conjugate vaccine is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in pediatric populations.
Meningococcal ACWY-CRM conjugate vaccine is currently in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial is designed to assess the vaccine's safety and immunogenicity compared to a polysaccharide vaccine in children.
Meningococcal ACWY-CRM conjugate vaccine has one completed Phase 3 clinical trial registered under NCT00329849. This trial, titled 'Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age,' enrolled 1,500 participants in Argentina. The study was active-controlled and included healthy volunteers aged 2 years and older.
No, Meningococcal ACWY-CRM conjugate vaccine is not the same as a polysaccharide vaccine. The conjugate vaccine is linked to a carrier protein, which typically enhances the immune response, particularly in young children. In the Phase 3 trial, the conjugate vaccine was compared against a polysaccharide vaccine to evaluate its safety and immunogenicity.